World-Renowned Smoking Cessation Scientist, Dr. Michael Cummings, to Present Keynote Address at 22nd Century Annual Sharehold...
April 18 2017 - 9:06AM
Business Wire
Dr. Cummings co-authored a report which
demonstrated improved stop smoking results when smokers combined
the use of Very Low Nicotine tobacco cigarettes with the nicotine
patch
22nd Century Group, Inc. (NYSE MKT: XXII), a plant
biotechnology company that is focused on tobacco harm reduction and
cannabis research, announced today that K. Michael Cummings, PhD,
MPH, Professor of Psychiatry and Behavioral Sciences at the Medical
University of South Carolina, will present the keynote address at
22nd Century Group’s annual shareholder meeting. The annual
shareholder meeting will be held on Saturday, April 29, 2017, at
2:00PM at the Buffalo Club in downtown Buffalo, New York. The
annual meeting will be open to shareholders of record as of the
close of business on March 10, 2017.
Recognized internationally for his work in tobacco epidemiology
and smoking cessation, Dr. Cummings is often called on to guide
global tobacco control policy initiatives. Dr. Cummings co-leads
the Tobacco Policy and Control research program at the Hollings
Cancer Center of the Medical University of South Carolina. As the
principal investigator of a project funded by the National
Institutes of Health, Dr. Cummings works to evaluate the
psychosocial, behavioral, and product-related impacts of the
tobacco control policies which are articulated through the World
Health Organization’s Framework Convention on Tobacco Control
(FCTC). This international project involves more than 20 countries
and over 100 research scientists.
Over a 30-year period, Dr. Cummings has served as a Cancer
Research Scientist and later the Chairman of the Roswell Park
Cancer Institute’s Department of Health Behavior where he helped to
establish the Smokers’ Quitline service in the State of New York. A
prolific scientific researcher, Dr. Cummings has authored or
co-authored over 420 scientific papers, including the landmark
reports for the Office of the Surgeon General, the National Cancer
Institute, and the International Agency for Research on Cancer. Dr.
Cummings is heavily involved in smoking cessation and nicotine
addiction research, co-authoring a report which demonstrated
improved stop smoking results when smokers combined the use of Very
Low Nicotine tobacco cigarettes with the nicotine patch: Tob Res.
2007. 9(11):1139-1146.
In 2009, Dr. Cummings’ extensive body of work in smoking
behavior and many contributions to the field of public health
earned him the prestigious Luther Terry Award, which is presented
by the American Cancer Society. Shareholders are encouraged to
attend 22nd Century’s annual shareholder meeting on April 29, 2017
and welcome to Dr. Cummings as he provides insight into the science
and policy surrounding tobacco control.
About 22nd Century Group, Inc.
22nd Century is a plant biotechnology company focused on
technology which allows it to increase or decrease the level of
nicotine in tobacco plants and the level of cannabinoids in
cannabis plants through genetic engineering and plant breeding. The
Company’s primary mission in tobacco is to reduce the harm caused
by smoking. The Company’s primary mission in cannabis is to develop
proprietary cannabis strains for important new medicines and
agricultural crops. Visit www.xxiicentury.com and
www.botanicalgenetics.com for more information.
Cautionary Note Regarding Forward-Looking Statements: This press
release contains forward-looking information, including all
statements that are not statements of historical fact regarding the
intent, belief or current expectations of 22nd Century Group, Inc.,
its directors or its officers with respect to the contents of this
press release, including but not limited to our future revenue
expectations. The words “may,” “would,” “will,” “expect,”
“estimate,” “anticipate,” “believe,” “intend” and similar
expressions and variations thereof are intended to identify
forward-looking statements. We cannot guarantee future results,
levels of activity or performance. You should not place undue
reliance on these forward-looking statements, which speak only as
of the date that they were made. These cautionary statements should
be considered with any written or oral forward-looking statements
that we may issue in the future. Except as required by applicable
law, including the securities laws of the United States, we do not
intend to update any of the forward-looking statements to conform
these statements to reflect actual results, later events or
circumstances, or to reflect the occurrence of unanticipated
events. You should carefully review and consider the various
disclosures made by us in our annual report on Form 10-K for the
fiscal year ended December 31, 2016, filed on March 8, 2017,
including the section entitled “Risk Factors,” and our other
reports filed with the U.S. Securities and Exchange Commission
which attempt to advise interested parties of the risks and factors
that may affect our business, financial condition, results of
operation and cash flows. If one or more of these risks or
uncertainties materialize, or if the underlying assumptions prove
incorrect, our actual results may vary materially from those
expected or projected.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170418005860/en/
22nd Century GroupInvestor Relations:IRTH CommunicationsAndrew
Haag, 866-976-4784xxii@irthcommunications.com
22nd Century (AMEX:XXII)
Historical Stock Chart
From Mar 2024 to Apr 2024
22nd Century (AMEX:XXII)
Historical Stock Chart
From Apr 2023 to Apr 2024